Navigation Links
Multiple Sclerosis: new MRI contrast medium enables early diagnosis in animal model
Date:8/1/2008

In an animal model of multiple sclerosis (MS), neuroradiologists and neurologists of the University hospitals of Heidelberg and Wrzburg have been able to visualize inflammatory tissue damage, most of which had remained unrecognized up to now, with the aid of a new contrast medium, Gadofluorine M, in magnetic resonance imaging. The scientists have published their results in the online edition of the renowned medical journal Brain.

In particular at the early stage of the disease, drug treatment is effective. Up to now, how-ever, an early diagnosis is frequently not established with certainty, especially if no (or very few) inflammatory lesions are present on MRI. "With this new contrast medium, we were able to visualize five to ten times more foci of inflammation in comparison to conventional MRI images and contrast media", reports Professor Dr. Martin Bendszus, Medical Director of the Department of Neuroradiology at the University hospital of Heidelberg.

Previously unrecognized patches of demyelination visible in MRI

MS is a chronic inflammatory disease of the central nervous system of unknown cause. It usually begins in young adults, and women are affected more frequently. In Germany, ap-proximately 120,000 patients are afflicted. MS is characterized by multiple inflammatory le-sions in which nerve fibers lose their myelin sheath. These patches of demyelination cause neurological malfunctions that may regress upon remyelination. At later stages, MS may re-sult in a loss of nerve fibers, leading to irreversible damage and persistent neurological symptoms. MRI plays a crucial role in the early diagnosis of MS and monitoring of the dis-ease.

The scientists from Heidelberg and Wrzburg examined brains and spinal cords of animals at different stages of the disease with the new contrast medium and found significantly more inflammatory lesions than with conventional contrast media. Examinations of tissue sections from these lesions showed that these were actually foci of inflammation. The application of this new contrast medium was clearly superior to conventional contrast media, especially for the spinal cord or optical nerve, nerve regions that are particularly difficult to examine on MRI.

New contrast medium accumulates better in MS lesions

The results of the study could help dramatically improve the diagnostic work-up in MS with a potential impact on early treatment. "MS is the most frequent cause of occupational disability and handicap in young adults", explains Professor Bendszus. "New therapies have a positive influence on the course of the disease, but are often not initiated at early stages since the diagnosis of MS is not yet established. "

The new contrast medium gadofluorine M supposedly visualizes MS lesions better because it binds especially well to certain components of the extracellular matrix of inflammatory foci. Because of this, it accumulates in these lesions in higher concentrations.

Now, the next objective of the interdisciplinary working group is to further develop the new MRI contrast medium for application in clinical practice. As of now, the contrast medium is not yet approved. Additional preclinical tests are necessary for the planned clinical application.


'/>"/>

Contact: Dr. Martin Bendszus
martin_bendszus@med.uni-heidelberg.de
49-622-156-7566
University Hospital Heidelberg
Source:Eurekalert

Related biology news :

1. Fast AFM probes measure multiple properties of biomolecules or materials simultaneously
2. Potential new target for multiple sclerosis therapy
3. Multiple resource management is focus of new technical report
4. Multiple species of bacteria may cause trachoma: Implications for treatment
5. The power of multiples: Connecting wind farms can make a more reliable - and cheaper - power source
6. New magnetic separation technique might detect multiple pathogens at once
7. Israeli scientists identify: Genes that affect responses of multiple sclerosis patients to copaxone
8. For honey bee queens, multiple mating makes a difference
9. Emphasis on conifer forests places multiple species at risk
10. Nicotinic receptors may be important targets for treatment of multiple addictions
11. Diverse genetic abnormalities lead to NF-κB activation in multiple myeloma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/3/2016)... 2016 Vigilant Solutions announces today that the ... Missouri solved two recent hit-and-run cases ... from Vigilant Solutions. Brian Wenberg explains, ... victim was walking out of a convenience store and witnessed an elderly male ... vehicle, striking his vehicle and leaving the scene.  In ...
(Date:2/2/2016)... 2, 2016 Checkpoint Inhibitors for Cancer ... Are you interested in the future of ... checkpoint inhibitors. Visiongain,s report gives those predictions to ... national level. Avoid falling behind in data ... and revenues those emerging cancer therapies can achieve. ...
(Date:2/1/2016)... Rising sales of consumer electronics ... intuitive gesture control market size ... consumer electronics coupled with new technological advancements to drive ... through 2020   --> ... advancements to drive global touchfree intuitive gesture control market ...
Breaking Biology News(10 mins):
(Date:2/4/2016)...  Sangamo BioSciences, Inc. (NASDAQ: SGMO ), the ... Edward Lanphier , Sangamo,s president and chief executive officer, ... ZFP Therapeutic ® development programs and an overview ... on Thursday, February 11, 2016, at the Leerink Partners ... is being held in New York ...
(Date:2/4/2016)... , Feb. 4, 2016 Beike Biotechnology, the ... medical institutions attended a ceremony in late 2015 to ... cell therapy in 2016. --> ... Translation Platform for Personalized Cell Therapy" was hosted by ... Production Center, both subsidiaries of Beike Biotechnology Co., Ltd. ...
(Date:2/4/2016)... --> --> ... pleased to provide the following update on recent corporate developments. ... last 3 months we have significantly increased our cash position ... As a result, we have positioned ourselves to execute on ... and expect that development to continue on schedule. ...
(Date:2/4/2016)... -- Sinovac Biotech Ltd. ("Sinovac" or the "Company") (NASDAQ: ... in China , today announced that ... on February 4, 2016 a preliminary non-binding proposal letter, ... PKU V-Ming ( Shanghai ) Investment Holdings ... ( Shenzhen ) Fund Management Co., Ltd., ...
Breaking Biology Technology: